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Abstract
 
Pathogenic mechanisms relevant to rheumatoid arthritis occur in the mouse model of collagen-
induced arthritis (CIA). Cytosolic phospholipase A
 
2
 
  
 
(cPLA
 
2
 
 
 
) releases arachidonic acid from
cell membranes to initiate the production of prostaglandins and leukotrienes. These inflamma-
tory mediators have been implicated in the development of CIA. To test the hypothesis that
cPLA
 
2
 
  
 
plays a key role in the development of CIA, we backcrossed cPLA
 
2
 
 
 
-deficient mice
on the DBA/1LacJ background that is susceptible to CIA. The disease severity scores and the
incidence of disease were markedly reduced in cPLA
 
2
 
 
 
-deficient mice compared with wild-
type littermates. At completion of the study, 
 
 
 
90% of the wild-type mice had developed dis-
ease whereas none of the cPLA
 
2
 
 
 
-deficient mice had more than one digit inflamed. Further-
more, visual disease scores correlated with severity of disease determined histologically. Pannus
formation, articular fibrillation, and ankylosis were all dramatically reduced in the cPLA
 
2
 
 
 
-
deficient mice. Although the disease scores differed significantly between cPLA
 
2
 
  
 
mutant and
wild-type mice, anti-collagen antibody levels were similar in the wild-type mice and mutant
littermates. These data demonstrate the critical role of cPLA
 
2
 
  
 
in the pathogenesis of CIA.
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Introduction
 
The murine model of collagen-induced arthritis (CIA)
 
* 
 
has
been used extensively to increase our understanding of au-
toimmune-mediated arthritis and identify potential new
therapeutic agents to treat rheumatoid arthritis. A series of
reports have suggested that cytosolic phospholipase A
 
2
 
 
 
(cPLA
 
2
 
 
 
), which releases arachidonic acid from the plasma
membrane to initiate the production of prostaglandins, leu-
kotrienes, and platelet-activating factor (PAF; 1, 2) might
be pivotal in the development of CIA. Mice deficient in
5-lipoxygenase–activating protein (FLAP), a protein re-
quired for the conversion of arachidonic acid to leuko-
trienes, developed less severe disease than wild-type ani-
mals despite generating antibodies to type II collagen (3).
Similarly, the severity of the disease was dramatically re-
duced when a potent leukotriene B
 
4 
 
receptor antagonist
was used (4). In both cases, the decrease in disease severity
due to leukotriene antagonism was maintained when IL-1
was added to potentiate inflammation and accelerate dis-
ease. The role of prostaglandins in arthritis is supported by
studies in the CIA model using cyclooxygenase (COX)-2–
deficient mice. COX-2 gene deletion reduced the inci-
dence and severity of CIA compared with both the wild-
type and COX-1–deficient mice. The COX-2–deficient
mice showed reduced anti-collagen type II antibody levels.
The COX-2–deficient mice remained resistant to disease
when the humoral response was bypassed through passive
transfer of anti-collagen II antibody (5). In another passive
transfer experiment, mice that are deficient for prostaglan-
din E
 
2 
 
receptor (EP)4 showed reduced disease in compari-
son to wild-type, EP1, EP2, and EP3 receptor–deficient
mice (6). Thus, the role of COX-2 in CIA appears to be
mediated at least in part by prostaglandin E
 
2 
 
acting through
the EP4. However, there are no published reports of selec-
tive COX-2 inhibitors showing benefit in the CIA model.
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Abbreviations used in this paper:
 
 CIA, collagen-induced arthritis; CII,
chicken collagen type II; COX, cyclooxygenase; cPLA
 
2
 
 
 
, cytosolic phos-
pholipase A
 
2
 
 
 
; EP, prostaglandin E
 
2 
 
receptor; FLAP, 5-lipoxygenase–acti-
vating protein; PAF, platelet-activating factor.T
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A subset of nonsteroidal antiinflammatory drugs, which in-
hibit both COX-1 and COX-2, are efficacious in the CIA
model if administered before onset of disease (7). Interest-
ingly, several laboratories have reported that combined in-
hibition of both leukotriene and prostaglandin production
is more effective at inhibiting disease progression (8, 9).
Additionally, a PAF receptor antagonist has been reported
to reduce the clinical and histopathological signs of disease
in CIA (10). Thus, given the role of prostaglandins, leuko-
trienes, and PAF in animal models of arthritis, we antici-
pated that cPLA
 
2
 
  
 
would be essential for the development
of CIA.
Although studies with cPLA
 
2
 
 
 
-deficient mice strongly
support the central role of this phospholipase A
 
2 
 
in prosta-
glandin, leukotriene, and PAF production (1, 2), cPLA
 
2
 
  
 
is
a member of a superfamily of PLA
 
2 
 
enzymes including
cPLA
 
2
 
  
 
and cPLA
 
2
 
  
 
(11, 12), calcium-independent PLA
 
2
 
(13), and numerous low molecular weight PLA
 
2
 
s (14).
Type II secretory PLA
 
2 
 
originally isolated from synovial
fluid is present at elevated levels in the synovial lining of
rheumatoid arthritis patients (15). Thus, PLA
 
2 
 
other than
cPLA
 
2
 
  
 
could conceivably be important in the pathogene-
sis of CIA. To assess the role of cPLA
 
2
 
  
 
in the CIA model,
we established the cPLA
 
2
 
 
 
-deficient mice on the suscepti-
ble DBA1/LacJ strain and studied the development of dis-
ease in cPLA
 
2
 
 
 
 
 
/
 
  
 
and cPLA
 
2
 
 
 
 
 
/
 
  
 
littermates.
 
Materials and Methods
 
Mice.
 
The Institutional Animal Care and Use Committee ap-
proved all animal procedures. cPLA
 
2
 
 
 
-deficient DBA/1LacJ
mice were obtained by crossing cPLA
 
2
 
 
 
-deficient C57BL/6 mice
(1) with the CIA-susceptible DBA/1LacJ mice for eight genera-
tions. DBA/1LacJ mice were originally obtained from The Jack-
son Laboratory. The cPLA
 
2
 
 
 
 
 
/
 
  
 
DBA/1LacJ mice were then in-
tercrossed to generate mice homozygous for the cPLA
 
2
 
 
 
mutation (cPLA
 
2
 
 
 
 
 
/
 
 
 
) and mice homozygous for the wild-type
cPLA
 
2
 
  
 
allele (cPLA
 
2
 
 
 
 
 
/
 
 
 
) for CIA experiments. In the CIA ex-
periments, female mice 10–15 wk of age were used. The mice
were maintained at a maximum of five per cage and were fed
mouse breeder chow and allowed access to water ad libitum. In
each experiment, mutant and wild-type mice were age matched.
The mice were crossed and bred at Taconic Farms and main-
tained for the CIA experiments in the animal unit at Wyeth Re-
search, Cambridge, MA. All animals were routinely serologically
tested and were negative for common pathogens.
 
Genotype Analysis by PCR.
 
The genotype of mice was deter-
mined by PCR using 100–200 ng genomic DNA prepared from
tail biopsies as template. The nucleotide sequence of the primers
was 5
 
 
 
-TTCTCTGGTGTGATGAAGGC-3
 
  
 
(cPLAF), 5
 
 
 
-
AAACTGACTGTAGCATCACAC-3
 
  
 
(cPLAR), 5
 
 
 
-ATCGC-
CTTCTTGACGAGTTC-3
 
  
 
(NeoF2). The primer set of
NeoF2 and cPLAR amplified a 570-bp fragment for the neo al-
lele and the set of cPLAF and cPLAR yielded a 224-bp fragment
specific for the wild-type allele. The reaction was performed us-
ing a Taq polymerase (GIBCO BRL) with 30 cycles of amplifi-
cation (45 s at 94
 
 
 
C, 1 min at 55
 
 
 
C, and 1 min plus 10 s autoex-
tension at 72
 
 
 
C).
 
Induction and Assessment of Arthritis.
 
Chicken collagen type II
(CII; Sigma-Aldrich) was dissolved in 0.01 N acetic acid and
emulsified in an equal volume of CFA containing 1 mg/ml heat-
killed 
 
Mycobacterium tuberculosis
 
 (Sigma-Aldrich). Arthritis was in-
duced by the initial immunization with 200 
 
 
 
g/100 
 
 
 
l emulsion
by an intradermal injection in the base of the tail. A boost 21 d
later with an aqueous solution of 200 
 
 
 
g/100 
 
 
 
l CII was admin-
istered intraperitoneally. On day 49, 28 d after the boost, 0.3 
 
 
 
g
murine rIL-1
 
  
 
diluted in PBS containing 1 mg/ml BSA was ad-
ministered subcutaneously. Individual experiments contained at
least 12 female cPLA
 
2
 
 
 
/
 
  
 
and cPLA
 
2
 
 
 
/
 
  
 
DBA/1LacJ mice per
group and all experiments were performed twice. Mice were
scored weekly, beginning 3 wk after primary CII immunization,
for signs of developing arthritis. The severity of the arthritis was
assessed using a visual scoring system. Each paw was scored on a
graded scale from 0 to 3: 0, normal paw; 1, swelling and/or red-
ness of one toe or finger joint; 2, swelling of two or more toes or
joints, or increased swelling; 3, severe swelling and/or ankylosis
throughout the entire paw. Each paw was graded and the four
scores were added such that the maximal score per mouse was 12.
On day 81, blood was collected for anti-collagen II ELISA testing
and paws were collected for histopathology.
Figure 1. Comparison of CIA symptoms in female wild-type and
cPLA2 -deficient mice. (A) Disease severity scores of arthritis for each
group of animals (n   12 for cPLA2  /  and n   17 for cPLA2  / ). Sig-
nificant differences to the wild-type group are marked with ** for P   0.01
and * for P   0.05 (two-tailed t test). (B) Percentage of female, wild-type,
and cPLA2 -deficient mice that developed arthritis in  1 digit. Of the
cPLA2 -deficient mice that developed arthritis, the disease was limited to
1 digit or less. In comparison, 16 out of 17 wild-type mice developed ar-
thritis in  1 digit. Significant differences to the wild-type group are
marked with *** for P   0.0001, ** for P   0.001, and * for P   0.05
(Fisher’s exact test). The results are from a single representative experiment.T
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Histological Techniques. For histological processing, paws were
fixed in phosphate buffer containing 10% formaldehyde and de-
calcified in sodium citrate. Paws were processed by routine meth-
ods to paraffin blocks. Specimens were sectioned at 6  m and
stained with hematoxylin and eosin according to the manufac-
turer’s protocol (Sigma-Aldrich). The sections were evaluated for
the degree of synovial hyperplasia, inflammatory cell infiltrate,
cartilage damage, pannus formation, bone erosion, fibrillation,
and ankylosis. The severity of the disease in the joint sections was
graded using a scoring system from 0 to 5: 0, within normal lim-
its; 1, minimal; 2, mild; 3, moderate; 4, marked; 5, severe. The
severity score for a paw was weighted based on the number of
joints within a paw receiving a specific score. Each paw was
graded and the score for four paws were added such that the
maximal score per mouse was 20.
Anti–Type II Collagen Antibody ELISA. IgG antibody levels
against the immunogen were measured by standard ELISA meth-
odology using peroxidase-conjugated secondary antibody and
Figure 2.  (A) Summary of
histopathological grades for syn-
ovial hyperplasia, inflammatory
cells, pannus formation, ankylo-
sis, and fibrillation of all joints of
cPLA2 -deficient and wild-type
mice. Significant differences to
the wild-type group are marked
with *** for P   0.0001, ** for
P   0.001, and * for P   0.01
(two-tailed  t  test). Concerning
ankylosis, t test was not applica-
ble because all cPLA2 -deficient
mice scored zero. (B) Histopa-
thology of hematoxylin and
eosin–stained joints of front paws
of cPLA2 -deficient and wild-
type mice. In A, the joints of
wild-type mice most frequently
showed severe pathology with
cartilage erosion, synovial in-
flammation, and formation of in-
vasive pannus (P). (B) The pan-
nus (see close-up in C) was
comprised of a mixture of
monocyte/macrophages (M) and
neutrophils (N). In B, the major-
ity of examined joints of
cPLA2 -deficient mice were
normal in appearance, with
smooth intact articular cartilage.
In D, the close up of B showed
few infiltrating cells, e.g., lym-
phocytes (Ly). Ac, articular cav-
ity; B, bone. original magnifica-
tion:  10 for A and B, bar   0.1
mm;  40 for C and D, bar  
0.01 mm.T
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substrate ABTS. Serum dilutions, 1/1,000, were chosen after
preliminary assays. The optical density was measured at 405 nm
using a Spectramax Plus 384 plate reader (Molecular Devices
Corporation). The anti–type II collagen concentrations were de-
termined by reference to standard curves of murine IgG, IgG1,
IgG2a, or IgG2b (Southern Biotechnology Associates, Inc.).
Statistical Analysis. Data are presented as the mean   SEM.
Clinical and histopathological scores and serum anti-CII IgG lev-
els were analyzed with Student’s t test. Incidence of mice that de-
veloped disease was analyzed with Fisher’s exact test. P values
 0.05 were considered significant.
Results
cPLA2 -deficient Mice Show Reduced Severity and Incidence
of CIA Compared with Wild-type Littermate Mice. To di-
rectly explore the pathophysiological role of cPLA2  in ar-
thritis, we backcrossed cPLA2 -deficient mice for at least
eight generations into the CIA-susceptible DBA/1LacJ
mouse strain (1, 16). The arthritic symptoms in cPLA2 -
deficient DBA/1LacJ mice and wild-type littermates were
studied after immunization with CII on day 0 and a boost
with CII on day 21. Mice were examined weekly after the
boost for signs of developing arthritis. The severity of the
arthritis was assessed using a visual scoring system. The dis-
ease severity scores and the incidence of disease were
markedly reduced in cPLA2 -deficient mice compared
with wild-type littermates (Fig. 1, A and B). By day 48,
only 8% of the cPLA2  /  mice had a score  1 compared
with 89% of the wild-type mice (Fig. 1 B). To test
whether we could accelerate disease in the cPLA2  / 
mice, IL-1  was administered to all mice on day 49 (17).
Although the severity of disease was increased in the wild-
type littermates, the cPLA2 -deficient mice were unaf-
fected by the inflammatory challenge. By the end of the
study on day 77, 94% of the wild-type animals had a dis-
ease severity  1 whereas none of the animals in the
cPLA2  /  group had  1 digit inflamed.
Histological Features of Immunized cPLA2   Mutant and
Wild-type Littermate Mice. An observer unaware of the ge-
notype of the animals scored the histopathology of both
front and rear paws. The severity of disease as determined
by the histological features correlated with the observed vi-
sual scores (Fig. 2 A). None of the cPLA2  /  mice that
were classified as nonarthritic had any evidence of arthritis
upon histological examination. Therefore, the histological
analysis of the paws confirmed the visual scoring results.
The joints of wild-type mice frequently showed severe pa-
thology with cartilage erosion, synovial inflammation, and
formation of invasive pannus (Fig. 2 B). New bone forma-
tion was also evident in late stage disease (unpublished data).
Pannus formation, fibrillation of the articular surface, and
eventual ankylosis are hallmarks of rheumatoid arthritis.
Mild to moderate pannus (76% of mice) and fibrillation of
the articular surface (47% of mice) were common in the
cPLA2  /  mice. In contrast, none of the cPLA2  /  mice
were observed to have more than minimal pannus forma-
tion or fibrillation of the articular cartilage. Similarly, anky-
losis was observed in 24% of the cPLA2  /  mice but in
none of the cPLA2  /  mice.
Immune Response Against CII in cPLA2 -deficient DBA/
1LacJ Mice. High levels of anti-CII antibodies accompany
the development of the disease (16). To investigate if the
reduced severity and incidence of arthritis in cPLA2  mu-
tant mice was due to the lack of an antibody response to
type II collagen, the anti-CII–specific levels of IgG in the
Figure 3. (A) Anti–type II collagen (CII) IgG, IgG1, IgG2a, and
IgG2b levels in serum of CII-immunized mice. No significant difference
was observed by genotype. (B.) Correlation of clinical scores, histopatho-
logical scores, and serum anti-CII total IgG levels. Wild-type and
cPLA2 -deficient mice are represented by black squares and red dia-
monds, respectively. Data from the same mouse are connected by lines
and some symbols overlap. Scores of synovial hyperplasia were chosen to
represent histopathological evaluations.T
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serum were determined at the termination of the CIA ex-
periment. Anti-CII antibody levels were similar in wild-
type mice and in cPLA2 -deficient littermates and did not
correlate with disease severity (Fig. 3 A). Although scores
of clinical and pathological analyses were segregated mostly
by genotypes of mice, IgG concentrations overlapped com-
pletely (Fig. 3 B).
Discussion
This study is the first to demonstrate the critical role of
cPLA2   as a key player in the pathogenesis of CIA.
cPLA2  /  mice show markedly reduced severity and inci-
dence of disease in CIA (Fig. 1) and these results were con-
firmed by histopathological evaluation (Fig. 2). The results
observed with the cPLA2  /  mice are similar to those
seen with FLAP /  mice. The reduced levels of infiltrating
cells in the joints of both the cPLA2  /  and FLAP / 
mice are consistent with the absence of leukotriene B4-
mediated chemotaxis (3). In addition, both gene-deleted
mice remained resistant to disease when IL-1  was added
to mice 28 d after the boost to accelerate disease. The
amount of anti–collagen type II IgG antibodies in cPLA2 
mutant mice was not different from the amount in wild-
type littermates (Fig. 3). These data are also consistent with
the results obtained with FLAP-deficient mice but appear
to differ with data from the COX-2–deficient mice. In the
COX-2 /  mice total anti–collagen type II Ig levels were
dramatically reduced ( 10-fold), but anti–collagen type II
IgG1 and IgG2 isotypes were only reduced by approxi-
mately twofold (5). Both the amount of anti-collagen total
IgG levels and IgG subclasses did not differ significantly be-
tween cPLA2  /  and wild-type mice. When the defect in
the humoral response was bypassed in the passive transfer
model, the COX-2 /  and EP4 /  mice remained resistant
to disease (5, 6). Thus, the collective studies using
cPLA2  / , COX-2 / , EP4 / , and FLAP /  mice sug-
gest that both prostaglandins and leukotrienes are important
in the pathogenesis of CIA and that inhibitors of cPLA2 
will be beneficial for individuals with rheumatoid arthritis
due to the simultaneous inhibition of multiple lipid media-
tors. Although no cPLA2  inhibitor is currently available
for clinical use, nutritional studies have been performed
where the omega-3 polyunsaturated fatty acids, eicosa-
penteanoic acid, and docosahexaenoic acid have shown
clinical benefit in numerous placebo-controlled studies of
rheumatoid arthritis (18, 19). The omega–3 acids may act
by reducing the arachidonic acid content of the phospho-
lipid membrane and thus decrease the ability of cells to
generate arachidonyl-derived proinflammatory mediators.
This would be analogous to blocking the release of arachi-
donic acid through the use of a cPLA2  antagonist. The
eicosapenteanoic and docosahexaenoic acids could exert
additional antiinflammatory effects by serving as the pre-
cursor to resolvins, which are newly reported antiinflam-
matory mediators generated through the action of aspirin-
acetylated COX-2 (20).
The role of cPLA2  extends beyond arthritis. For exam-
ple, cPLA2  has been shown to be essential for osteoclast
formation and LPS-induced bone resorption (21). This ef-
fect of cPLA2  might be mediated by prostaglandin E2 be-
cause the EP4 is required for bone resorption and osteoclast
formation (22). Thus, cPLA2  may play a role in bone re-
sorption associated with osteoporosis as well as rheumatoid
arthritis. These data support that a prospective cPLA2  in-
hibitors may have the potential activity of a disease-modi-
fying antirheumatic drug. Furthermore, the importance of
cPLA2  has been demonstrated in models of respiratory
disease including anaphylaxis, bronchial hyperreactivity,
adult respiratory distress syndrome, and pulmonary fibrosis
using the cPLA2  /  mice (1, 23, 24). A reduction in in-
farct size has also been observed after cerebral ischaemia (2).
Consequently, cPLA2  is an ideal target for a potent selec-
tive inhibitor for the treatment of numerous diseases, in-
cluding rheumatoid arthritis.
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